Summary & Overview
HCPCS C9305: Nipocalimab-aahu Injection, 3 mg
HCPCS Level II code C9305 identifies nipocalimab-aahu, billed as a 3 mg injectable dose. As a newly codified biologic therapy, this code standardizes reporting for administration of nipocalimab-aahu across outpatient infusion and clinic-based injection settings. Uniform coding facilitates claims processing, utilization tracking, and payer coverage determinations for this parenteral treatment.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines what readers need to know about coding and billing representation for nipocalimab-aahu: clinical context for an injectable biologic, common service locations, and how standardized HCPCS Level II reporting supports reimbursement workflows and policy alignment.
Readers will find benchmarks and policy-oriented context relevant to national payer interactions, including which payer groups are evaluated and typical administrative considerations for outpatient administration. Where input data is not provided, the text notes the absence: for example, associated taxonomies, ICD-10 diagnoses, and related codes are not available in the input. The focus remains on national-level implications for coding, billing, and operational handling of HCPCS Level II code C9305.
Billing Code Overview
HCPCS Level II code C9305 describes the medication nipocalimab-aahu, billed per 3 mg injection. This code represents a single-dose injectable biologic product intended for parenteral administration.
Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion or injection setting, which may include hospital outpatient departments, physician offices, ambulatory infusion centers, or other clinic-based injection sites.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with a documented autoimmune hemolytic anemia (AIHA) or a severe, treatment-refractory IgG-mediated condition presents to an outpatient infusion center for administration of a novel monoclonal antibody, nipocalimab-aahu. The medication is billed as C9305 per 3 mg increment. The clinical workflow begins with verification of the order by the prescribing hematologist or immunologist, confirmation of diagnosis and pre-infusion labs (CBC, renal and hepatic panels), and review of prior immunotherapy responses. A registered nurse performs an allergy and medication reconciliation and obtains baseline vital signs. The patient is counseled on potential infusion reactions and consents to treatment. The infusion pharmacist prepares the dose under sterile conditions and performs a final check. The nurse administers the intravenous injection/infusion, monitors vitals and for infusion-related adverse events throughout and for a short observation period after completion. Documentation includes the drug name nipocalimab-aahu, billed as C9305 with quantity reflecting total milligrams administered (three mg units), lot number, route, site, pre/post vitals, and any reactions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or specialty clinics. Common clinical modifiers applied to the claim, when relevant, include 52, 53, 55, 56, and 78 to indicate reduced services, discontinued procedures, post-operative care by another physician, or return to the operating/procedure room for related interventions.